P
Philip J. Lee
Researcher at University College London
Publications - 74
Citations - 6880
Philip J. Lee is an academic researcher from University College London. The author has contributed to research in topics: Fabry disease & Glycogen storage disease. The author has an hindex of 36, co-authored 74 publications receiving 6462 citations. Previous affiliations of Philip J. Lee include St George's Hospital & University of Cambridge.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.
Christine M. Eng,Nathalie Guffon,William R. Wilcox,Dominique P. Germain,Philip J. Lee,S. Waldek,Louis R. Caplan,Gabor E. Linthorst,Robert J. Desnick +8 more
TL;DR: Recombinant alpha-galactosidase A replacement therapy cleared microvascular endothelial deposits of globotriaosylceramide from the kidneys, heart, and skin in patients with Fabry's disease, reversing the pathogenesis of the chief clinical manifestations of this disease.
Journal ArticleDOI
Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy
B Sachdev,Toshihiro Takenaka,Hiroyuki Teraguchi,Chuwa Tei,Philip J. Lee,WJ McKenna,Perry M. Elliott +6 more
TL;DR: The prevalence of a potentially treatable cause of hypertrophy, Anderson-Fabry disease, in a HCM referral population is determined and its recognition is important given the advent of specific replacement enzyme therapy.
Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy - Reply
Perry M. Elliott,B Sachdev,WJ McKenna,Toshihiro Takenaka,Hiroyuki Teraguchi,Chuwa Tei,Philip J. Lee +6 more
Journal ArticleDOI
Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
Dominique P. Germain,Stephen Waldek,Maryam Banikazemi,Maryam Banikazemi,David A. Bushinsky,Joel Charrow,Robert J. Desnick,Philip J. Lee,Thomas W. Loew,Anouk C. Vedder,Rekha Abichandani,William R. Wilcox,Nathalie Guffon +12 more
TL;DR: Long-term agalsidase beta therapy stabilizes renal function in patients without renal involvement at baseline, maintains reduction of plasma GL-3, and sustainsGL-3 clearance in capillary endothelial cells and multiple renal cell types.
Journal ArticleDOI
Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.
William R. Wilcox,Maryam Banikazemi,Nathalie Guffon,Stephen Waldek,Philip J. Lee,Gabor E. Linthorst,Robert J. Desnick,Dominique P. Germain +7 more
TL;DR: In this article, the safety and efficacy results of a multicenter phase 3 trial of recombinant human α-galactosidase A (rh-αGalA) replacement in patients with Fabry disease were reported.